Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
2015 ◽
Vol 33
(15_suppl)
◽
pp. 5578-5578
Keyword(s):
Phase I
◽
2018 ◽
Vol 151
(3)
◽
pp. 422-427
◽
2017 ◽
Vol 80
(6)
◽
pp. 1239-1247
◽
2018 ◽
Vol 82
(6)
◽
pp. 1087-1088
Keyword(s):